Clinical Efficacy and Safety of Intralesional Bevacizumab in Dermatology: Insights from a Systematic Review

Fereshte Rastegarnasab; Najmeh   Tavousi; Mahsa  Pourmahdi-Boroujeni; Kimia Afshar; Shadi Behfar; Bahareh  Abtahi-Naeini

doi:10.5826/dpc.1504a5430

Clinical Efficacy and Safety of Intralesional Bevacizumab in Dermatology: Insights from a Systematic Review

Authors

Fereshte Rastegarnasab Isfahan university of medical sciences
Najmeh Tavousi Isfahan university of medical sciences
Mahsa Pourmahdi-Boroujeni Isfahan university of medical sciences
Kimia Afshar Isfahan university of medical sciences
Shadi Behfar Rafsanjan university of medical sciences
Bahareh Abtahi-Naeini Isfahan university of medical sciences

Keywords:

Bevacizumab, Intralesional, Avastin, Anti-Vascular Endothelial Growth Factors, Anti-VEGF

Abstract

Introduction: Bevacizumab is a humanized monoclonal antibody specifically targeting the vascular endothelial growth factor (VEGF). In addition to cancer and ophthalmology, bevacizumab has other off-label uses. Among these, the treatment of hereditary hemorrhagic telangiectasia and hemangioma can be mentioned.

Objectives: Although there are reports of successful treatments by bevacizumab, there is no systematic review on the topical use of this medication in dermatology. Therefore, this study aimed to investigate this topic.

Methods: A systematic search on topical bevacizumab was done with MeSh-based keywords on online databases of PubMed, Scopus, and Web of Science in December 2022. The records were evaluated, and the eligible articles were selected.

Results: We reviewed related studies, and the disease name, treatment protocol (injection dosage and intervals), outcomes, and complications were summarized for conclusions.

Conclusions: In this study, we systematically reviewed related papers and summarized the use of bevacizumab in dermatology in four categories, including hereditary hemorrhagic telangiectasia, vascular malformation, vascular proliferation, and others (lichen planus, and basal cell carcinoma).

References

Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012;33(3):349-51. DOI: 10.1016/j.amjoto.2011.07.012. PMID: 21917353.

Mukherji SK. Bevacizumab (Avastin). AJNR Am J Neuroradiol. 2010;31(2):235-6. DOI: 10.3174/ajnr.A1987. PMID: 20037132.

Sidell DR, Balakrishnan K, Best SR, Zur K, Buckingham J, De Alarcon A, et al. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope. 2021;131(6):E1941-e9. DOI: 10.1002/lary.29343. PMID: 33405268.

Sajib S, Zahra FT, Lionakis MS, German NA, Mikelis CM. Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions. Angiogenesis. 2018;21(1):1-14. DOI: 10.1007/s10456-017-9583-4. PMID: 29110215.

Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017;12(5):599-610. DOI: 10.1007/s11523-017-0518-1. PMID: 28801849.

Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol. 2011;13(10):710-4. DOI: 10.1007/s12094-011-0720-z. PMID: 21975331.

Kabunga RR, Onyango J, Ruvuma S, Arunga S. Outcome of intravitreal Avastin® injections in patients with macular oedema in Uganda: a cohort study. Eye (Lond). 2022;36(Suppl 1):45-50. DOI: 10.1038/s41433-022-02006-5. PMID: 35590055.

Fazel F, Nikpour H, Pourazizi M. Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial. Biomed Res Int. 2020;2020:6794391. DOI: 10.1155/2020/6794391. PMID: 32016118.

Fazel F, Oliya B, Mirmohammadkhani M, Fazel M, Yadegarfar G, Pourazizi M. Intravitreal Injections of Bevacizumab Plus Methotrexate versus Bevacizumab Alone for the Treatment of Diabetic Macular Edema: A Randomized, Sham-Controlled Trial. J Curr Ophthalmol. 2020;32(2):164-9. DOI: 10.4103/JOCO.JOCO_101_20. PMID: 32671300.

Bancalari A, Schade R. Update in the Treatment of Retinopathy of Prematurity. Am J Perinatol. 2022;39(1):22-30. DOI: 10.1055/s-0040-1713181. PMID: 32544962.

Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, et al. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology. 2022;129(10):1120-8. DOI: 10.1016/j.ophtha.2022.05.019. PMID: 35660415.

Abtahi-Naeini B, Saffaei A, Hadian M. Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents. J Res Pharm Pract. 2019;8(3):178-9. DOI: 10.4103/jrpp.JRPP_19_58. PMID: 31728351.

Bowers EMR, Lee S. Treatment of tongue telangiectasia in a patient with hereditary haemorrhagic telangiectasia. BMJ Case Rep. 2020;13(11). DOI: 10.1136/bcr-2020-238485. PMID: 33139375.

Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, et al. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. JAMA. 2016;316(9):943-51. DOI: 10.1001/jama.2016.11724. PMID: 27599329.

Sabry HH, Sorour NE, Akl EM. Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. J Dermatolog Treat. 2020;31(3):279-84. DOI: 10.1080/09546634.2019.1590521. PMID: 30835573.

Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012;122(3):495-7. DOI: 10.1002/lary.22501. PMID: 22147664.

Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121(3):636-8. DOI: 10.1002/lary.21415. PMID: 21344445.

Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope. 2012;122(5):953-5. DOI: 10.1002/lary.23230. PMID: 22447341.

Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, et al. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs. 2014;6(3):794-9. DOI: 10.4161/mabs.28025. PMID: 24481211.

Chen St, Karnezis T, Davidson TM, Chen Iv S, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121(3):644-6. DOI: 10.1002/lary.21345. PMID: 21344447.

Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2009;119(5):988-92. DOI: 10.1002/lary.20159. PMID: 19194865.

Dheyauldeen S, Østertun Geirdal A, Osnes T, Vartdal LS, Dollner R. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope. 2012;122(6):1210-4. DOI: 10.1002/lary.23303. PMID: 22565282.

Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double‐blind, randomized, placebo‐controlled trial. Head neck. 2015;37(6):783-7. DOI: 10.1002/hed.23655. PMID: 24595923.

Kalinina MP, Grachev NS, Kumskova MA, Timofeeva OK. Successful treatment of recurrent epistaxis with submucosal bevacizumab therapy in a female patient with hereditary hemorrhagic telangiectasia. Pediatric Hematology/Oncology and Immunopathology. 2014;13(4):75-8.

Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol. 2012;269(2):531-6. DOI: 10.1007/s00405-011-1721-9. PMID: 21805356.

Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope. 2010;120(2):432-5. DOI: 10.1002/lary.20757. PMID: 19998344.

Hwang J, Lee YK, Burm JS. Treatment of Tongue Lymphangioma with Intralesional Combination Injection of Steroid, Bleomycin and Bevacizumab. Arch Craniofac Surg. 2017;18(1):54-8. DOI: 10.7181/acfs.2017.18.1.54. PMID: 28913305.

Kinzinger MR, Strong EB, Bernard J, Steele TO. Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma. Ann Otol Rhinol Laryngol. 2018;127(12):969-73. DOI: 10.1177/0003489418802288. PMID: 30246545.

Schlosser RJ, Woodworth BA, Gillespie MB, Day TA. Endoscopic resection of sinonasal hemangiomas and hemangiopericytomas. ORL J Otorhinolaryngol Relat Spec. 2006;68(2):69-72. DOI: 10.1159/000091092. PMID: 16428897.

Pourazizi M, Kabiri S, Abtahi-Naeini B. Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis. J Res Pharm Pract. 2017;6(3):190-1. DOI: 10.4103/jrpp.JRPP_17_38. PMID: 29026847.

Steeples LR, Bonshek R, Morgan L. Intralesional bevacizumab for cutaneous capillary haemangioma associated with pregnancy. Clin Exp Ophthalmol. 2013 May 1;41(4). DOI: 10.1111/j.1442-9071.2012.02881.x. PMID: 22957786.

Ablanedo-Terrazas Y, Alvarado-de la Barrera C, Ormsby CE, Ruiz-Cruz M, Reyes-Terán G. Intralesional bevacizumab in patients with human immunodeficiency virus-associated Kaposi's sarcoma in the upper airway. Laryngoscope. 2015;125(4):E132-7. DOI: 10.1002/lary.24988. PMID: 25345840.

Mahmoud MM, Afifi MM. Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus. Eur J Oral Sci. 2016;124(2):119-26. DOI: 10.1111/eos.12251. PMID: 26892241.

Tanese K. Diagnosis and Management of Basal Cell Carcinoma. Curr Treat Options Oncol. 2019;20(2):13. DOI: 10.1007/s11864-019-0610-0. PMID: 30741348.

Gaitanis G, Bassukas I. Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma. J Eur Acad Dermatol Venereol. 2014;28(8):1117-21. DOI: 10.1111/jdv.12327. PMID: 25243268.